Sapient Capital LLC Sells 46,450 Shares of Liquidia Technologies, Inc. $LQDA

Key Points

• Sapient Capital LLC reduced its stake in Liquidia Technologies by 38.0%, owning 75,750 shares worth approximately $944,000 after selling 46,450 shares in the second quarter.
• Liquidia Technologies experienced significant analyst activity, with two analysts rating it a Strong Buy, and overall consensus rating of Buy with a price target of $32.11.
• The company's latest earnings report showed a revenue of $8.84 million, significantly exceeding expectations, despite reporting a loss of ($0.49) EPS.

Sapient Capital LLC lessened its holdings in shares of Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) by 38.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,750 shares of the company's stock after selling 46,450 shares during the period. Sapient Capital LLC owned approximately 0.09% of Liquidia Technologies worth $944,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Goldman Sachs Group Inc. lifted its holdings in shares of Liquidia Technologies by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company's stock valued at $12,703,000 after purchasing an additional 82,955 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in Liquidia Technologies by 18.7% in the 1st quarter. Boothbay Fund Management LLC now owns 662,873 shares of the company's stock valued at $9,777,000 after acquiring an additional 104,215 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Liquidia Technologies by 446.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 461,248 shares of the company's stock valued at $6,803,000 after acquiring an additional 376,872 shares in the last quarter. Woodline Partners LP lifted its stake in Liquidia Technologies by 1.6% in the 4th quarter. Woodline Partners LP now owns 421,683 shares of the company's stock valued at $4,959,000 after acquiring an additional 6,791 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in Liquidia Technologies by 21.4% in the 4th quarter. Two Sigma Investments LP now owns 381,237 shares of the company's stock valued at $4,483,000 after acquiring an additional 67,134 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Jefferies Financial Group assumed coverage on Liquidia Technologies in a research note on Friday, August 15th. They issued a "buy" rating and a $43.00 target price on the stock. Wells Fargo & Company boosted their price target on Liquidia Technologies from $25.00 to $31.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Bank of America lowered their price target on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research report on Wednesday, June 11th. Raymond James Financial boosted their price target on Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a research report on Wednesday, August 13th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Liquidia Technologies in a research report on Tuesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $32.11.

Insider Transactions at Liquidia Technologies

In other Liquidia Technologies news, Director Paul B. Manning sold 328,268 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $28.78, for a total value of $9,447,553.04. Following the completion of the sale, the director owned 430,828 shares of the company's stock, valued at approximately $12,399,229.84. This trade represents a 43.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Raman Singh sold 45,524 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $25.81, for a total value of $1,174,974.44. Following the completion of the transaction, the director owned 31,255 shares in the company, valued at $806,691.55. This represents a 59.29% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 881,097 shares of company stock valued at $23,689,864. Company insiders own 26.50% of the company's stock.

Liquidia Technologies Price Performance

LQDA traded down $0.89 on Friday, reaching $23.78. The stock had a trading volume of 4,384,298 shares, compared to its average volume of 2,134,676. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -13.99 and a beta of 0.22. The firm has a 50-day moving average of $23.11 and a 200-day moving average of $17.52. The company has a current ratio of 2.49, a quick ratio of 2.41 and a debt-to-equity ratio of 9.84. Liquidia Technologies, Inc. has a fifty-two week low of $9.71 and a fifty-two week high of $29.94.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The company had revenue of $8.84 million during the quarter, compared to analyst estimates of $3.90 million. Liquidia Technologies's revenue for the quarter was up 141.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).